This is
Kineret
A valuable asset for the treatment of IL-1
mediated diseases1
Kineret is indicated for the treatment of several diseases associated with IL-1-mediated inflammation.2
Kineret was first approved in 2001 for the treatment of Rheumatoid Arthritis (RA). Since then, its indications and use have expanded to a broad spectrum of inflammatory conditions. Kineret is included in international treatment guidelines for the management of several autoinflammatory diseases.3,4
Kineret is a targeted treatment that neutralises the biological activity of both IL-1α and IL-1β2
Kineret acts by competitively inhibiting the biological activity of interleukin-1α and interleukin-1β2
Kineret indications2
Kineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids. Kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs).2
Kineret is indicated for the treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate.2
Kineret is indicated for the treatment of CAPS, including: Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA), Muckle-Wells Syndrome (MWS) and Familial Cold Autoinflammatory Syndrome (FCAS).2
Kineret is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone.2
Kineret is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) ≥ 6 ng/ml2
Well established safety profile1
The safety profile of Kineret has been well established in several placebo-controlled, randomised trials, as well as clinical use following its first marketing authorisation in 20012
References
- Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018 Jan;281(1):8-27. doi: 10.1111/imr.12621. PMID: 29247995; PMCID: PMC5756628.
- Swedish Orphan Biovitrum AB (publ). Kineret summary of product characteristics [SmPC]. Latest version available from: https:// www.ema.europa.eu/en/documents/product-information/kineret-epar-product-information_en.pdf
- Fautrel B, Mitrovic S, De Matteis A, et al. EULAR/PReS recommendations for the diagnosis and management of Still’s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still’s disease. Annals of the Rheumatic Diseases Published Online First: 24 September 2024.
- Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016 Apr;75(4):644–51.
- EU Risk Management Plan for Kineret (anakinra), Table 21. Available at: https://www.ema.europa.eu/en/documents/rmp/kineret- epar-risk-management-plan_en.pdf